Li B.; Jia Z.; Huang Z.; Xue J.; Wang Y.; Guo C.; Si X.; Chen Z.; Li J.; Chen R.; Bie Z.; De Giglio A.; Christopoulos P.; Liang N.; Li S., Adjuvant crizotinib treatment selected by patient-derived organoids in a patient with stage IIIA adenocarcinoma with novel LRRTM4-ALK fusion: a case report, «TRANSLATIONAL LUNG CANCER RESEARCH», 2023, 12, pp. 2322 - 2329 [Scientific article]Open Access
Riudavets M.; Auclin E.; Mosteiro M.; Dempsey N.; Majem M.; Prelaj A.; Lopez-Castro R.; Bosch-Barrera J.; Pilotto S.; Escalera E.; Tagliamento M.; Mosquera J.; Zalcman G.; Aboubakar Nana F.; Ponce S.; Albarran-Artahona V.; Dal Maso A.; Spotti M.; Mielgo X.; Mussat E.; Reyes R.; Benitez J.-C.; Lupinacci L.; Duchemann B.; De Giglio A.; Blaquier J.B.; Audigier-Valette C.; Scheffler M.; Nadal E.; Lopes G.; Signorelli D.; Garcia-Campelo R.; Menis J.; Bluthgen V.; Campayo M.; Recondo G.; Besse B.; Mezquita L.; Planchard D., Association Between Lung Immune Prognostic Index and Durvalumab Consolidation Outcomes in Patients With Locally Advanced Non‐Small‐Cell Lung Cancer, «CLINICAL LUNG CANCER», 2023, 000, pp. 1 - 11 [Scientific article]
De Giglio A.; Deiana C.; Di Federico A., Bone-specific response according to MDA criteria predicts immunotherapy efficacy among advanced non-small cell lung cancer (NSCLC) patients, «JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY», 2023, 149, pp. 1835 - 1847 [Scientific article]Open Access
Raschi, Emanuel; Rossi, Simone; De Giglio, Andrea; Fusaroli, Michele; Burgazzi, Flavio; Rinaldi, Rita; Potena, Luciano, Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians, «DRUG SAFETY», 2023, 46, pp. 819 - 833 [Scientific article]Open Access
Nigro M.C.; Marchese P.V.; Deiana C.; Casadio C.; Galvani L.; Di Federico A.; De Giglio A., Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review, «LUNG CANCER: TARGETS AND THERAPY», 2023, 14, pp. 11 - 25 [Scientific article]
Mosca, Mirta; Conci, Nicole; Di Federico, Alessandro; Tateo, Valentina; Favorito, Valentina; Zappi, Arianna; Gelsomino, Francesco; De Giglio, Andrea, First-Generation Epidermal Growth Factor Receptor Inhibitors Plus Antiangiogenic Drugs Versus Third-Generation Epidermal Growth Factor Receptor Inhibitors in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis, «JCO PRECISION ONCOLOGY», 2023, 7, pp. 1 - 16 [Scientific article]
Mosca M.; Nigro M.C.; Pagani R.; De Giglio A.; Di Federico A., Neutrophil-to-Lymphocyte Ratio (NLR) in NSCLC, Gastrointestinal, and Other Solid Tumors: Immunotherapy and Beyond, «BIOMOLECULES», 2023, 13, Article number: 1803 , pp. 1 - 15 [Scientific article]Open Access
Rossi S.; Gelsomino F.; Rinaldi R.; Muccioli L.; Comito F.; Di Federico A.; De Giglio A.; Lamberti G.; Andrini E.; Mollica V.; D'Angelo R.; Baccari F.; Zenesini C.; Madia P.; Raschi E.; Cortelli P.; Ardizzoni A.; Guarino M., Peripheral nervous system adverse events associated with immune checkpoint inhibitors, «JOURNAL OF NEUROLOGY», 2023, 270, pp. 2975 - 2986 [Scientific article]Open Access
Di Federico, Alessandro; De Giglio, Andrea; Gelsomino, Francesco; Sperandi, Francesca; Melotti, Barbara; Ardizzoni, Andrea, Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis, «JOURNAL OF THE NATIONAL CANCER INSTITUTE», 2023, 115, pp. 29 - 42 [Scientific article]
Di Federico A.; Ricciotti I.; Favorito V.; Michelina S.V.; Scaparone P.; Metro G.; De Giglio A.; Pecci F.; Lamberti G.; Ambrogio C.; Ricciuti B., Resistance to KRAS G12C Inhibition in Non-small Cell Lung Cancer, «CURRENT ONCOLOGY REPORTS», 2023, 25, pp. 1017 - 1029 [Scientific article]
De Giglio A.; Ricciuti B.; Metro G., The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks, «DRUGS IN CONTEXT», 2023, 12, Article number: 2022-11-4 , pp. 1 - 3 [Scientific article]Open Access
Metro G.; De Giglio A.; Ricciuti B.; Siringo M.; Marinelli D.; Gelibter A.; Pecci F.; Berardi R.; Cantini L.; Di Federico A.; Andrini E.; Mosca M.; Lamberti G.; Brambilla M.; Mountzios G., Advanced non-small-cell lung cancer: how to manage EGFR and HER2 exon 20 insertion mutation-positive disease, «DRUGS IN CONTEXT», 2022, 11, Article number: A1 , pp. 1 - 10 [Scientific article]
De Giglio A.; Di Federico A.; Deiana C.; Ricciuti B.; Brambilla M.; Metro G., Advanced non-small-cell lung cancer: how to manage non-oncogene disease, «DRUGS IN CONTEXT», 2022, 11, Article number: 2022-2-4 , pp. 1 - 14 [Scientific article]Open Access
Di Federico A.; Rizzo A.; Carloni R.; De Giglio A.; Bruno R.; Ricci D.; Brandi G., Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 361 - 369 [Scientific article]
De Giglio, A.; Orlando, V.; Andrini, E.; Ricciuti, B.; Lamberti, G.; Chiari, R., Challenges in the management of advanced NSCLC among Italian oncologists: a 2019 national survey unfolds regional disparities, «TUMORI», 2022, not reported, pp. 3008916211069412 - 3008916211069418 [Scientific article]
